Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
The Annals of Thoracic Surgery|November 18, 2019
Cardiac Magnetic Resonance-Derived Metrics Are Predictive of Liver Fibrosis in Fontan PatientsPhillip M Trusty, Zhenglun Alan Wei, Jack Rychik, et al.
Archives of Pathology & Laboratory Medicine|January 28, 2022
Neoplastic Cellularity Assessment in Molecular TestingKelly A Devereaux, Rhona J Souers, Rondell P Graham, et al.
JCO Precision Oncology|August 13, 2020
Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer PredispositionSuzanne P MacFarland, Kristin Zelley, Lea F Surrey, et al.
Pediatric Blood & Cancer|March 21, 2020
miRNA expression can classify pediatric thyroid lesions and increases the diagnostic yield of mutation testingAime T Franco, Emmanuel Labourier, Kenny Kwabena Ablordeppey, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2019
Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 casesOscar Lopez-Nunez, Ivy John, Ryane N Panasiti, et al.
Thyroid : Official Journal of the American Thyroid Association|October 2, 2019
Extrathyroidal Extension is an Important Predictor of Regional Lymph Node Metastasis in Pediatric Differentiated Thyroid CancerNeil K Jain, Sogol Mostoufi-Moab, Colin P Hawkes, et al.
JAMA Otolaryngology-- Head & Neck Surgery|September 23, 2021
Thyroid Lobectomy for T1 Papillary Thyroid Carcinoma in Pediatric PatientsChad K Sudoko, Carolyn M Jenks, Andrew J Bauer, et al.
American Journal of Medical Genetics. Part A|July 4, 2025
Multiple Genomic Technologies Validate Rare Novel Variant and Direct Medical Care in Vascular AnomaliesLuciana Daniela Garlisi Torales, Kristina Woodis, Allison Britt, et al.
Pediatric Blood & Cancer|February 10, 2021
BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakersPayal Jain, Lea F Surrey, Joshua Straka, et al.
Cancer|April 20, 2023
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcomaKristina A Cole, Heba Ijaz, Lea F Surrey, et al.
Pageof 9